Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects
NCT05066516Phase 1Completed
- Sponsor
- Korea University Anam Hospital
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IN-C009 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Korea University Anam Hospital. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours and Area Under the Plasma Concentration-Time Curve at 72 hours. Started Jun 2020; status: completed.
02
Drugs
IN-C009
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05066516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066516.